Earnings Release2026-04-29
HANALL BIOPHARMA CO.,LTD Earnings
한올바
한올바이오파마
009420
Signal Score
50C — Neutral
Score50 / 100
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2555
Risk-adjusted indicator based on 2555 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Revenue: 40,031 million KRW (10.7% YoY growth)
- • Operating Profit: 839 million KRW (vs. -2,016 million KRW in 25.4Q, a 141.6% QoQ increase)
3 more figures — unlock with API access
AI Analysis Summary
Developer & Pro plans
Risk Factors
Developer & Pro plans
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Historical pattern data via REST API
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.
AI-processed analysis. Based on: 연결재무제표기준영업(잠정)실적(공정공시) . Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.